NEOGAP secures EU patent for innovative personalised immunotherapy technology
In December of last year, NEOGAP announced that the company’s patent application for the European market was being prepared for approval through a ”Notice of Allowance”. NEOGAP has now obtained final approval from the European Patent Office for their pioneering approach to multiplying T-cells outside the body using their EpiTCer® technology and the production of tumour-specific T-cells. The patent, valid until 2038, ensures that NEOGAP’s EpiTCer® technology is patent protected across various markets.
”We are pleased that NEOGAP has been granted this patent in Europe. Our continuous evaluation of intellectual property rights ensures the protection of our unique cancer therapies. Our focus is to develop our treatments for personalised immunotherapy, to increase survival rates and improve the quality of life for cancer patients,” says Samuel Svensson, CEO of NEOGAP.
For more information, please contact:
Samuel Svensson, CEO
Phone: +46 733 54 21 94
About NEOGAP Therapeutics
NEOGAP Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using patient’s own cells. The therapy is based on the company’s two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognise and attack the selected tumor-specific targets. NEOGAP is located at the Centre for Molecular Medicine at the Karolinska Institute in Stockholm. To learn more about NEOGAP and its cutting-edge research, please visit the company’s website at neogap.se and follow NEOGAP on LinkedIn.
Access our Swedish press release on Cision’s press room
To read our press release in Swedish, please navigate to our press room on Cision, where you can access all of our latest news and announcements.